Regulatory Compliance

Rome – October 05, 2026 -- Temu has signed a Memorandum of Understanding with Italy's Central Inspectorate for Fraud Repression and Quality Protection of Agri-Food Products (ICQRF) to strengthen protection of Geographical Indications (GIs) on its online marketplace.

Agreement targets prevention and seller guidance on GI products

The MoU, signed alongside an event marking ICQRF's 40th anniversary, establishes a cooperation framework focused on prevention, seller education and information exchange. Temu and ICQRF will meet periodically to evaluate and develop joint initiatives aimed at strengthening GI protection and preventing unfair commercial practices.

Abu Dhabi – October 05, 2026 -- Hong Kong's Independent Commission Against Corruption (ICAC) and the United Nations Office on Drugs and Crime (UNODC) jointly launched the first global guidebook on corruption risk management in prison systems, unveiled on October 1 at the 15th United Nations Congress on Crime Prevention and Criminal Justice in Abu Dhabi.

ICAC Commissioner frames prisons as the justice system's last line of defence

ICAC Commissioner Woo Ying-ming, who also serves as President of the International Association of Anti-Corruption Authorities (IAACA), co-launched the guide with UNODC Executive Director Monica Juma. Drawing on three decades of experience as former Commissioner of Correctional Services of Hong Kong, Woo stated that a corrupt prison environment endangers law enforcement officers and inmates while undermining rehabilitation and social stability.

Taipei – October 05, 2026 -- AnnJi Pharmaceutical Co., Ltd. (TPEx: 7754) is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial for AJ201, an oral small molecule targeting spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, a rare inherited neuromuscular disorder with no FDA-approved treatment.

AJ201 becomes the only investigational SBMA therapy in Phase 3 development worldwide

AnnJi submitted the Phase 3 protocol to the U.S. FDA under its active Investigational New Drug application and will now move to activate U.S. trial sites. The global, multicenter, randomized, double-blind, placebo-controlled ROMA-KD study is designed to evaluate efficacy and safety in ambulatory patients with symptomatic SBMA, with approximately 200 patients expected to enroll worldwide and the United States serving as a key region.

Auckland – October 05, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that its Symphony wound care product achieved a 55% complete closure rate for diabetic foot ulcers within 12 weeks, compared with 35% for standard of care alone, in a peer-reviewed randomized controlled trial published in the International Wound Journal.

Trial enrolled 143 patients across 10 U.S. sites to test Symphony against standard care

The prospective, multicenter RCT randomized patients with Wagner Grade 1 or 2 diabetic foot ulcers to receive either weekly Symphony plus standard of care or standard of care alone, for up to 12 weeks or until complete closure. Ulcers ranged from full-thickness skin wounds to deeper lesions extending into ligaments, tendons, joint capsules or deep fascia.

Singapore – – October 05, 2026 -- S&P Global Ratings has launched a new risk-assessment framework for digital asset lending vaults, a market that has grown to $10 billion in deposits as of September 2026 from $1.5 billion two years earlier. The Vault Risk Assessment (VRA) delivers independent, forward-looking analysis of impairment risk for investors in blockchain-based lending vehicles that pool deposits and deploy them according to defined strategies, functioning much like traditional fixed income funds.

Hiroshima – October 03, 2026 -- Ractigen Therapeutics presented first-in-human data showing its systemically delivered small activating RNA (saRNA), RAG-18, produced 3.5- to 5.3-fold increases in sarcolemmal utrophin expression in boys with Duchenne muscular dystrophy (DMD), marking the first clinical proof-of-mechanism for RNA activation (RNAa) in a monogenic disease. The data were disclosed in a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society (WMS 2026) in Hiroshima, Japan.

Vancouver – October 03, 2026 -- Silvercorp Metals Inc. (TSX/NYSE American: SVM) secured shareholder approval for all resolutions at its annual general and special meeting, including a special resolution to amend its corporate Articles to align with Hong Kong Stock Exchange listing rules.

Shareholders back Hong Kong Stock Exchange alignment with 95.74% approval

The special resolution authorizing amendments to Silvercorp's Articles passed with 96,389,543 votes in favor, representing 95.74% support, against 4,287,268 votes opposed. The amendments bring the Company's constating documents in line with listing rules governing securities on The Stock Exchange of Hong Kong, a move the Company first disclosed in news releases issued September 22 and October 03, 2026.

Columbus, Ohio – October 03, 2026 -- The Franklin County Correctional Center II, known as Jackson Pike, passed its annual inspection by the Bureau of Adult Detention of the Ohio Department of Rehabilitation and Correction with no deficiencies noted, following a review conducted October 03, 2026.

Ohio regulators found no compliance gaps across facility operations

The inspection covered facility operations, safety measures, sanitary conditions and compliance with applicable state standards, including protocols tied to health care delivery. The Franklin County Sheriff's Office operates the facility, with Armor Health serving as its correctional healthcare partner.

Memphis, Tenn. – October 03, 2026 -- HigherVisibility, a Memphis-based digital marketing agency, published a line-by-line diff of Google's October 1 revision to its AI-generated content guidance, identifying an edit it says carries more weight than the headline-grabbing fact-check mandate.

Manual review now explicitly covers four metadata fields

Most coverage centered on Google's new statement that manually fact-checking all AI-generated content before publishing is "critical." HigherVisibility's comparison against the archived version shows the sentence that follows rewrote the scope of that obligation to name title elements, meta descriptions, structured data, and image alt text specifically. Those four surfaces are the ones ecommerce catalogs, programmatic SEO builds, and agency pipelines most often generate automatically, often without a human reviewing the output.

Cambridge, Mass. – – October 03, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) received a Nasdaq Staff Determination on October 03, 2026, confirming it failed to meet the $35 million minimum market value of listed securities (MVLS) requirement by its October 03, 2026 deadline, triggering a potential delisting from The Nasdaq Capital Market.

Company to appeal delisting threat before Nasdaq Hearings Panel

NeuroSense intends to timely request a hearing before a Nasdaq Hearings Panel under Nasdaq Listing Rule 5800 Series to seek additional time to regain MVLS compliance. A timely hearing request automatically stays any suspension of trading and the filing of a Form 25-NSE with the SEC while the Panel reviews the case. The Panel has discretion to grant an exception of up to 180 days from the October 1 Staff Determination date.